T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype - Takeaways - MDSpire

T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype

Share

  • 1

    STAT3 signaling is crucial for T cell functions, including metabolism, apoptosis, differentiation, and cytokine production.

  • 2

    Mutations in STAT3 are common in T-cell cancers, particularly in T-cell large granular lymphocytic leukemias, with a mutation rate of approximately 40%.

  • 3

    The Y640F and N647I variants of STAT3 exhibit gain-of-function phenotypes, with Y640F having more extensive transcriptome-wide effects.

  • 4

    Common STAT3 mutants induce a T regulatory 1 gene program, characterized by IL-10 expression and factors that suppress T-cell responses.

  • 5

    Tr1 skewing is observed in both mouse models and human patients with T-cell malignancies, suggesting a mechanism for immune evasion.

Original Source(s)

T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype

  • by Aaron B. Schultz, Molly Dalzell, Luis Nivelo, Sarah E. Henrickson, Alejandro V. Villarino

  • May 5, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...